Trump SLASHES Drug Prices — Pharma Finally Loses

Calculator displaying the message 'PRICE DROP' — PHARMA FINALLY LOSES

President Trump’s bold drug pricing deals have slashed the costs of GLP-1 weight-loss and fertility drugs in half, delivering real relief to families crushed by sky-high healthcare bills.

Story Highlights

Trump’s TrumpRx.gov platform halves the price of GLP-1 drugs from over $1,000 to as low as $245/month for Medicare users, easing the burdens of diabetes and obesity.
Fertility medications like Gonal-F drop 84% via the EMD Serono deal, saving thousands per IVF cycle for families building the next generation of patriots.
CMS Medicare Director Chris Klomp confirms Americans previously unable to afford prescriptions now have access to them at pharmacy counters.
Revived Most-Favored-Nation pricing and tariff leverage force Big Pharma to prioritize American patients over global profiteering.

Trump Strikes Back Against Pharma Gouging

President Donald J. Trump announced deals with Eli Lilly, Novo Nordisk, and EMD Serono in 2025, reviving his first-term Most-Favored-Nation model abandoned by Biden.

GLP-1 drugs like Zepbound fell from $1,088 to $346 monthly on TrumpRx.gov, launched in February 2026. Medicare secures them at $245 per month for all indications, including obesity.

This counters years of list prices exceeding $1,000 amid shortages, putting relief directly in patients’ hands. Families skipped fills at 25% rates before these wins.

CMS Director Confirms Pharmacy Counter Savings

CMS Medicare Director Chris Klomp stated on Fox Business that prices halved a couple of months after the deals. GLP-1s for diabetes and weight loss now cost half as much as before.

Fertility drugs save thousands per cycle; Gonal-F dropped to $168 per pen, down from higher out-of-pocket costs averaging $3,000-$7,000 per IVF round.

Cetrotide fell from $316 to $22.50. TrumpRx aggregates these for cash-pay Americans, bypassing insurance red tape that fueled inflation under prior policies.

Americans paying less as Trump drug pricing push slashes GLP-1, fertility medicine costs, official says https://t.co/9Zt7wC06qp

— FOX Business (@FoxBusiness) April 7, 2026

Fertility Wins Bolster Family Values

In October, Trump secured an 84% discount on IVF from EMD Serono through tariff exemptions for U.S. manufacturing.

Ovidrel prices plunged from $251 to $84. This targets infertility, hitting millions, often privately insured families, able to pursue $21,600 cycles.

Administration leverages FDA priority vouchers and market access for concessions. Such moves align with conservative priorities, supporting traditional families against government overreach that left costs unchecked.

Discounts remain conditional; Zepbound refills within 45 days avoid a price hike to $699. Introductory GLP-1 rates from $199-$349 expire in spring 2026. States eye Medicaid expansions.

Critics claim overlaps with coupons, yet Klomp highlights novel access that solves real skips. In the long term, negotiations sustain Medicare while boosting adherence.

Pharma Trades for American Priorities

Eli Lilly offers Zepbound, Mounjaro at $245-$389 for Medicare; Emgality pens at $299, down $443.

Novo Nordisk matches on Ozempic and Wegovy. Pharma gains coverage volume and tariff relief, trading high list prices for domestic jobs.

White House touts massive immediate savings, fulfilling Trump’s promises against globalist pricing. AMCP notes obesity coverage influences states; ASRM clarifies select IVF drugs only, not full cycles.